Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Phosphorus containing other than solely as part of an...
Patent
1991-08-21
1992-07-28
Berch, Mark L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Phosphorus containing other than solely as part of an...
514938, A61K 9107, A61K 31685
Patent
active
051341301
ABSTRACT:
A composition for the treatment of patients having Acquired Immune Deficiency Syndrome comprising approximately 2 to 7 percent by weight soybean oil and approximately 1 to 2 percent by weight egg phosphatide and a method for the parenteral administration of this composition is disclosed.
REFERENCES:
patent: 3169094 (1965-02-01), Wretlind
patent: 4073943 (1978-02-01), Wretlind
patent: 4101673 (1965-02-01), Chang
patent: 4157404 (1979-06-01), Yano et al.
patent: 4372949 (1983-02-01), Kodama et al.
patent: 4465693 (1984-08-01), Strauss et al.
patent: 4474773 (1984-10-01), Shinitzky et al.
patent: 4677099 (1987-06-01), Shinitzky et al.
patent: 4711902 (1987-12-01), Serno
Groves, Chem. Abs. 103, 27187.
Change, II, Chem. Abs. 84, 169684 (1974).
"Body composition studies in patients with the acquired immunodeficiency syndrome.sup.1-3 "; Donald P. Kotler, MD, Jack Wang, MS, and Richard N. Pierson, Jr., MD; the American Journal of Clinical Nutrition 42: Dec. 1985, pp. 1255-1265.
"Does Nutritional Deficiency Predispose to Acquired Immune Deficiency Syndrome?"; V. K. Jain, M. B. B. S. and R. K. Chandra, M.D., F.R.C.P.; Nutrition Research, vol. 4, pp. 537-543, 1984.
"High Density Lipoprotein As a Protective Factor Against Coronary Heart Disease"; T. Gordon, W. P. Castelli, M.D., M. C. Hjortland, Ph.D., W. B. Kannel, M.D., T. R. Dawber, M.D.; The American Journal of Medicine, vol. 62, May 1977.
"Enteropathy Associated with the Acquired Immunodeficiency Syndrome"; D. P. Kotler, M.D., H. P. Gaetz, M.D., M. Lange, M.D., E. B. Klein, M.D., and P. R. Holt, M.D.; Annals of Internal Medicine, Oct. 1984, vol. 101, No. 4.
"Response to Total Parenteral Nutrition in the Extremely Malnourished Patient"; P. M. Starker, M.D., P. A. LaSala, M.D., R. Armour Forse, M.D., Ph.D., J. Askanazi, M.D., D. H. Elwyn, Ph.D., and J. M. Kinney, M.D.; Journal of Parenteral and Enteral Nutrition, vol. 9, No. 3, Accepted for publication Nov. 10, 1984.
Correspondence "Effects of a novel Compound (AL 721) on HTLV-III Infectivity in Vitro"; P. S. Sarin, R. C. Gallo, D. I. Scheer, F. Crews, A. S. Lippa; The New England Journal of Medicine, Nov. 14, 1985, pp. 1289-1290.
"Lipid composition and fluidity of the human immunodeficiency virus"; Roland C. Aloia et al.; Medical Sciences, vol. 85, pp. 900-904, Feb. 1988.
"Interaction of Vesicular Stomatitis Virus with Lipid Vesicles: Depletion of Cholesterol and Effect on Virion Membrane Fluidity and Infectivity"; N. F. Moore et al.; Journal of Virology, Aug. 1978, pp. 320-329.
"A special lipid mixture for membrane fluidization"; M. Lyte and M. Shinitzky; 1985 Elsevier Science Publishers B.V., pp. 133-138.
"Human Immunodeficiency Virus (HIV-1) Cytotoxicity: Perturbation of the Cell Membrane and Depression of Phospholipid Synthesis"; William S. Lynn et al.; Virology 163, pp. 43-51 (1988).
Askanazi Jeffrey
Leathem William D.
Shaw Howard L.
Abbott Laboratories
Berch Mark L.
LandOfFree
Lipid emulsion for treating aids does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipid emulsion for treating aids, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipid emulsion for treating aids will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1687121